CEA, Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis, 75010 Paris, France ; Université Paris Diderot, Sorbonne Paris Cité, IUH, Hopital Saint-Louis, UMR_E5, 75010 Paris, France.
J Immunol Res. 2014;2014:359748. doi: 10.1155/2014/359748. Epub 2014 Mar 31.
We here review the current data on the role of HLA-G in cancer based on recent findings of an unexpected antitumor activity of HLA-G in hematological malignancies. For the past decade, HLA-G has been described as a tumor-escape mechanism favoring cancer progression, and blocking strategies have been proposed to counteract it. Aside from these numerous studies on solid tumors, recent data showed that HLA-G inhibits the proliferation of malignant B cells due to the interaction between HLA-G and its receptor ILT2, which mediates negative signaling on B cell proliferation. These results led to the conjecture that, according to the malignant cell type, HLA-G should be blocked or conversely induced to counteract tumor progression. In this context, we will here present (i) the dual role of HLA-G in solid and liquid tumors with special emphasis on (ii) the HLA-G active structures and their related ILT2 and ILT4 receptors and (iii) the current knowledge on regulatory mechanisms of HLA-G expression in tumors.
我们在这里根据 HLA-G 在血液恶性肿瘤中具有抗肿瘤活性的新发现，综述了 HLA-G 在癌症中的作用的现有数据。在过去的十年中，HLA-G 被描述为一种有利于癌症进展的肿瘤逃逸机制，并且已经提出了阻断策略来对抗它。除了这些关于实体瘤的大量研究外，最近的数据表明，HLA-G 通过 HLA-G 与其受体 ILT2 之间的相互作用抑制恶性 B 细胞的增殖，该相互作用介导 B 细胞增殖的负信号。这些结果导致推测，根据恶性细胞类型，HLA-G 应该被阻断或相反地诱导以抵抗肿瘤进展。在这方面，我们将在这里介绍 (i) HLA-G 在实体瘤和液体瘤中的双重作用，特别强调 (ii) HLA-G 的活性结构及其相关的 ILT2 和 ILT4 受体，以及 (iii) 肿瘤中 HLA-G 表达的调控机制的现有知识。
Zotero 插件